- Home
- TURN vs XGN Comparison
TURN vs XGN Comparison
Compare TURN & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TURN
- XGN
- Stock Information
- Founded
- TURN 1981
- XGN 2002
- Country
- TURN United States
- XGN United States
- Employees
- TURN N/A
- XGN N/A
- Industry
- TURN Finance/Investors Services
- XGN Medical Specialities
- Sector
- TURN Finance
- XGN Health Care
- Exchange
- TURN Nasdaq
- XGN Nasdaq
- Market Cap
- TURN 49.6M
- XGN 138.3M
- IPO Year
- TURN N/A
- XGN 2019
- Fundamental
- Price
- TURN $8.00
- XGN $9.17
- Analyst Decision
- TURN
- XGN Strong Buy
- Analyst Count
- TURN 0
- XGN 5
- Target Price
- TURN N/A
- XGN $12.40
- AVG Volume (30 Days)
- TURN 33.2K
- XGN 192.7K
- Earning Date
- TURN 02-26-2018
- XGN 11-11-2025
- Dividend Yield
- TURN N/A
- XGN N/A
- EPS Growth
- TURN N/A
- XGN N/A
- EPS
- TURN 0.29
- XGN N/A
- Revenue
- TURN $488,011.00
- XGN $58,862,000.00
- Revenue This Year
- TURN N/A
- XGN $22.28
- Revenue Next Year
- TURN N/A
- XGN $14.03
- P/E Ratio
- TURN $17.34
- XGN N/A
- Revenue Growth
- TURN 277.43
- XGN 3.89
- 52 Week Low
- TURN $3.12
- XGN $2.38
- 52 Week High
- TURN $5.01
- XGN $10.34
- Technical
- Relative Strength Index (RSI)
- TURN 91.31
- XGN 45.47
- Support Level
- TURN $4.60
- XGN $8.97
- Resistance Level
- TURN $8.74
- XGN $10.28
- Average True Range (ATR)
- TURN 0.24
- XGN 0.40
- MACD
- TURN 0.31
- XGN -0.15
- Stochastic Oscillator
- TURN 82.51
- XGN 15.27
About TURN 180 Degree Capital Corp.
180 Degree Capital Corp is active in the financial services domain. It is a non-diversified closed-end management investment company whose objective is to achieve long-term capital appreciation by making venture capital investments. It focuses its investments on companies commercializing and integrating products enabled by disruptive technologies mainly in the life sciences, precision medicine, and health industries.
About XGN Exagen Inc.
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.